NO310070B1 - Benzo[g]kinolinderivater, fremstilling herav, farmasöytiske midler og preparater inneholdende disse samt anvendelse av derivatene for fremstilling av medikamenter - Google Patents

Benzo[g]kinolinderivater, fremstilling herav, farmasöytiske midler og preparater inneholdende disse samt anvendelse av derivatene for fremstilling av medikamenter Download PDF

Info

Publication number
NO310070B1
NO310070B1 NO980043A NO980043A NO310070B1 NO 310070 B1 NO310070 B1 NO 310070B1 NO 980043 A NO980043 A NO 980043A NO 980043 A NO980043 A NO 980043A NO 310070 B1 NO310070 B1 NO 310070B1
Authority
NO
Norway
Prior art keywords
formula
compound
acid addition
free base
salt form
Prior art date
Application number
NO980043A
Other languages
English (en)
Norwegian (no)
Other versions
NO980043D0 (no
NO980043L (no
Inventor
Peter Neumann
Paul Pfaeffli
Max Peter Seiler
Robert Swoboda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513880.6A external-priority patent/GB9513880D0/en
Priority claimed from GBGB9603988.8A external-priority patent/GB9603988D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO980043D0 publication Critical patent/NO980043D0/no
Publication of NO980043L publication Critical patent/NO980043L/no
Publication of NO310070B1 publication Critical patent/NO310070B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO980043A 1995-07-07 1998-01-05 Benzo[g]kinolinderivater, fremstilling herav, farmasöytiske midler og preparater inneholdende disse samt anvendelse av derivatene for fremstilling av medikamenter NO310070B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9513880.6A GB9513880D0 (en) 1995-07-07 1995-07-07 Organic compounds
GBGB9603988.8A GB9603988D0 (en) 1996-02-26 1996-02-26 Organic compounds
PCT/EP1996/002969 WO1997003054A1 (en) 1995-07-07 1996-07-05 BENZO[g]QUINOLINE DERIVATIVES

Publications (3)

Publication Number Publication Date
NO980043D0 NO980043D0 (no) 1998-01-05
NO980043L NO980043L (no) 1998-01-05
NO310070B1 true NO310070B1 (no) 2001-05-14

Family

ID=26307342

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980043A NO310070B1 (no) 1995-07-07 1998-01-05 Benzo[g]kinolinderivater, fremstilling herav, farmasöytiske midler og preparater inneholdende disse samt anvendelse av derivatene for fremstilling av medikamenter

Country Status (28)

Country Link
US (1) US5885988A (da)
EP (1) EP0839136B1 (da)
JP (1) JPH11509197A (da)
KR (1) KR19990028757A (da)
CN (1) CN1193964A (da)
AR (1) AR004672A1 (da)
AT (1) ATE201199T1 (da)
AU (1) AU703325B2 (da)
BR (1) BR9609326A (da)
CA (1) CA2224436A1 (da)
CO (1) CO4750662A1 (da)
CZ (1) CZ1698A3 (da)
DE (1) DE69612852T2 (da)
DK (1) DK0839136T3 (da)
ES (1) ES2158327T3 (da)
GR (1) GR3036346T3 (da)
HU (1) HUP9802937A3 (da)
IL (1) IL122854A (da)
NO (1) NO310070B1 (da)
NZ (1) NZ313606A (da)
PE (1) PE1998A1 (da)
PL (1) PL324106A1 (da)
PT (1) PT839136E (da)
RU (1) RU2158738C2 (da)
SK (1) SK1798A3 (da)
TR (1) TR199800011T1 (da)
TW (1) TW357143B (da)
WO (1) WO1997003054A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711043D0 (en) 1997-05-29 1997-07-23 Ciba Geigy Ag Organic compounds
AU5265599A (en) * 1998-04-08 1999-11-01 Takeda Chemical Industries Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
CA2246791A1 (en) * 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
RU2221785C2 (ru) * 1998-09-22 2004-01-20 Яманоути Фармасьютикал Ко., Лтд. Гетероциклическое производное, фармацевтическая композиция, его содержащая, и промежуточный продукт
PL346795A1 (en) * 1998-09-22 2002-02-25 Yamanouchi Pharma Co Ltd Cyanophenyl derivatives
GB9902938D0 (en) * 1999-02-10 1999-03-31 Novartis Ag Organic compounds
PE20030240A1 (es) * 2001-07-09 2003-04-16 Novartis Ag DERIVADOS DE BENZO [g] QUINOLINA
FI20031454A0 (fi) 2003-10-06 2003-10-06 Juvantia Pharma Ltd Oy Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja
KR100594234B1 (ko) 2003-12-05 2006-06-30 삼성전자주식회사 편광 현상을 이용하여 해상도를 향상시킬 수 있는 포토마스크 및 그 제조방법
EP2269610A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US8067410B2 (en) 2008-06-27 2011-11-29 H. Lundbeck A/S Phenolic and catecholic amines and prodrugs thereof
EP3634406B1 (en) 2017-05-12 2023-09-06 Board of Trustees of The Southern Illinois University on behalf of Southern Illinois University Edwardsville 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
US11912687B2 (en) 2017-05-12 2024-02-27 Board of Trustees of the Southern Illinois University 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP3972600B1 (en) 2019-05-21 2026-02-18 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7099717B2 (ja) 2019-09-30 2022-07-12 株式会社理研バイオ ソマトスタチン受容体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630902A5 (en) * 1977-01-24 1982-07-15 Sandoz Ag Process for preparing novel derivatives of 1,2,3,4,4a,10b-hexahydrobenzo(f)isoquinoline.
LU88619I2 (fr) * 1981-10-16 1995-07-10 Sandoz Ag QUINAGOLIDE, éventuellement sous forme de sel, par exemple du chlorhydrate
SU1109393A1 (ru) * 1983-04-28 1984-08-23 Ордена Трудового Красного Знамени Институт Физики Ан Бсср Способ получени 9-диэтиламинобензо/ @ /феноксазинона-5 или его производных
HU193979B (en) * 1984-06-12 1987-12-28 Sandoz Ag Process for producing naphtoxazine derivatives and pharmaceutical compositions containing them
NL8702680A (nl) * 1986-11-21 1988-06-16 Sandoz Ag Nieuwe benzogchinolinen en werkwijzen voor het bereiden en toepassen van deze verbindingen.
WO1993024471A1 (en) * 1992-06-02 1993-12-09 Whitby Research, Inc. Substituted naphthoxazines useful as dopaminergics
WO1994021614A1 (en) * 1993-03-24 1994-09-29 Merck & Co., Inc. SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS
DE4329776A1 (de) * 1993-09-03 1995-03-09 Sandoz Ag Naphthoxazine, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
IL122854A (en) 2000-12-06
CO4750662A1 (es) 1999-03-31
AU6612096A (en) 1997-02-10
EP0839136A1 (en) 1998-05-06
NO980043D0 (no) 1998-01-05
CA2224436A1 (en) 1997-01-30
MX9710530A (es) 1998-03-31
TR199800011T1 (xx) 1998-04-21
PE1998A1 (es) 1998-02-14
KR19990028757A (ko) 1999-04-15
RU2158738C2 (ru) 2000-11-10
AR004672A1 (es) 1999-03-10
AU703325B2 (en) 1999-03-25
JPH11509197A (ja) 1999-08-17
HUP9802937A2 (hu) 1999-10-28
IL122854A0 (en) 1998-08-16
CZ1698A3 (cs) 1998-04-15
DE69612852D1 (de) 2001-06-21
NZ313606A (en) 1999-07-29
ES2158327T3 (es) 2001-09-01
EP0839136B1 (en) 2001-05-16
CN1193964A (zh) 1998-09-23
GR3036346T3 (en) 2001-11-30
NO980043L (no) 1998-01-05
DK0839136T3 (da) 2001-08-06
DE69612852T2 (de) 2001-10-04
PL324106A1 (en) 1998-05-11
PT839136E (pt) 2001-09-28
HUP9802937A3 (en) 2002-10-28
ATE201199T1 (de) 2001-06-15
US5885988A (en) 1999-03-23
TW357143B (en) 1999-05-01
WO1997003054A1 (en) 1997-01-30
BR9609326A (pt) 1999-05-25
SK1798A3 (en) 1998-06-03

Similar Documents

Publication Publication Date Title
EP0839136B1 (en) BENZO[g]QUINOLINE DERIVATIVES
JPH1059967A (ja) 新規3−(ピペリド−4−イル)−1,2−ベンゾイソオキサゾール及び3−(ピペラジン−4−イル)−1,2−ベンゾイソオキサゾール化合物、その製造方法、並びにそれを含有する医薬組成物
RU2191776C2 (ru) Эрголиновые производные, способ их получения, фармацевтическая композиция
US6355642B1 (en) Tetrahydrobenzindole compounds
JP4762250B2 (ja) フェニル−ピペラジンメタノン誘導体
EP1446399B1 (en) Piperazine derivatives having sst1 antagonistic activity
CN1041360A (zh) 新的吡啶基和嘧啶基衍生物
JPH0723364B2 (ja) 新規な1−ピペラジンカルボキサミド誘導体
US4243666A (en) 4-Amino-2-piperidino-quinazolines
JPH02138266A (ja) 6‐フェニル‐3‐(ピペラジニルアルキル)‐2,4(1h,3h)‐ピリミジンジオン誘導体
JPH037257A (ja) ピリジン誘導体及びそれを有効成分とする向精神剤
KR20010042904A (ko) 광학 활성 테트라하이드로벤즈인돌 유도체
JPH0225481A (ja) 2―[(4―ピペリジニル)メチル]―1,2,3,4―テトラヒドロイソキノリン誘導体、その製造方法およびその治療への適用
JP5193033B2 (ja) ヒスタミンh3受容体薬剤、製剤及び治療的使用
CN101384260A (zh) 哌嗪衍生物
US5081128A (en) 2,3-dihydro-1h-isoindole derivatives and their application in therapy
JP2864489B2 (ja) 喘息治療剤
JP2004231514A (ja) 5−ht7受容体結合能を有し、かつ代謝的に安定なテトラヒドロベンズインドール誘導体
MXPA97010530A (en) Benzo (a) quinol derivatives
JPH04103572A (ja) 4―フェニル―2―(1―ピペラジニル)ピリジン誘導体

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN JANUARY 2003